Melatonin MT-1-receptor immunoreactivity in the human eye

P Meyer, M Pache, K U Loeffler, L Brydon, R Jockers, J Flammer, A Wirz-Justice, E Savaskan

Aim: To examine the distribution of melatonin 1a (MT1) receptors in the human eye.

Methods: Seven normal human eyes were examined by immunohistochemical staining of paraffin sections, using an anti-MT1 primary antibody and an ABC detection system.

Results: MT1 receptor immunoreactivity (MT1-IR) was detected primarily in the inner segments of rods and cones and in retinal ganglion cells. In addition, MT1-IR was present in the adventitia of retinal arteries and veins, including the papillary region, but absent in ciliary and choroidal vessels. Mild staining of corneal endothelial cells and keratocytes was observed in all but two eyes.

Conclusion: MT1-IR is present in various ocular tissues with the highest density in photoreceptor cells and ganglion cells. The physiological function of these receptors deserves further investigation.

Melatonin is synthesised in the pineal gland and in the retina in a diurnal rhythm with increased levels at night. Experimental studies suggest that retinal melatonin is synthesised in photoreceptor cells under the control of a circadian oscillator located within the retina itself. The function of melatonin in the human eye, however, is as yet only partially disclosed. In vertebrates, melatonin mediates dark-adaptive regulation of retinomotor movements, circadian disc shedding in photoreceptor cells, regulation of horizontal cell sensitivity to light, and modulation of dopamine release. As in the pineal gland, retinal melatonin may also act as a signal of darkness. Furthermore, a role as a scavenger of free radicals within the photoreceptors has been proposed for melatonin.

In mammals, the specific functions of melatonin are mediated by two different subtypes of G protein coupled receptors, the melatonin 1a (MT1) and melatonin 1b (MT2) receptor. Meanwhile, specific polyclonal antibodies against MT1 have become available, and MT1 receptor expression has been studied in rodents using immunocytochemistry and in situ hybridisation. For a better understanding of the role of melatonin in the human eye, it is essential to determine its precise target cells. Therefore we examined the distribution of MT1 receptors in normal human eyes by means of immunohistochemistry.

MATERIALS AND METHODS

Tissue preparation

Human tissue samples
Paraffin embedded human eyes, fixed in 4% paraformaldehyde, were obtained post mortem from seven patients without ophthalmological or neurological diseases (M:F = 1:6; mean age 81.7 years (SD 12.5). The cause of death was either heart failure or pneumonia in all cases. The sample collection was approved by the ethics committee criteria and followed the tenets of the Helsinki Declaration. Tissue samples were cut in a sagittal plane including the optic nerve head and pupil and 4 µm thick serial sections were made with a microtome.

Immunohistochemistry

Sections were mounted on gelatine chromalum coated glass slides, and deparaffinised. The antigen was finally visualised by peroxidase staining using the peroxidase substrate 3- amino-9-ethylcarbazole (AEC), as previously reported. The optimum concentration of the primary antibody was previously determined to be 1:100. The affinity purified polyclonal antibody used to specifically detect MT1 was developed against the C terminus of the receptor and the antibody recognition of native MT1 receptor has been ascertained. Moreover, the antibody has been applied successfully in previous immunohistochemical experiments. To test the specificity of the primary antibody, control sections were stained simultaneously, following the same procedure with the exception that the primary antibody was omitted. Tissue of the hippocampus served as positive control. Moreover, we performed α-smooth muscle actin staining in adjacent control sections using specific monoclonal antibodies (Monoclonal Anti-α-Smooth Muscle Actin, Sigma Chemicals Co, St Louis, MO, USA) to distinguish between the different layers of the vessel wall.

All sections were assessed for localisation and intensity of specific immunoreactivity on a semiquantitative scale of + to + + + by two blind observers (details are given in Tables 1–3). In case of disagreement, consent was achieved by discussion.

RESULTS

Ocular tissue

Various cell types of cornea, retina, as well as retinal arteries and veins displayed specific MT1-IR. Serial control sections omitting the primary antibody revealed no immune reaction. α-Smooth muscle actin staining was observed in the smooth muscle cells of the tunica media in all ocular vessels.

Retina

In the whole retina, some variation in intensity was observed, but specific immunoreactivity was seen in the following compartments (see also Table 1).

Ganglion cells

In all eyes, about 90% of ganglion cells revealed MT1-IR in their somata and dendritic processes. MT1 staining varied between + to ++ + in intensity and showed a fine granular homogeneous distribution in the perinuclear area (see Fig 1).
Inner nuclear layer
In all but one case, single cells with MT1-IR were located in the inner nuclear layer (3–21 cells in the whole retina per section) (compare Fig 1).

Photoreceptor cells
All photoreceptor cells revealed distinct MT1-IR (++ to +++ in intensity) in their inner segments. Cell somata and outer segments appeared unlabelled. MT1-IR extended as an immunoreactive band throughout the complete photoreceptor cell layer (Fig 1).

In all cases, slight MT1 labelling of the inner plexiform layer was observed, whereas in the outer plexiform layer only weak immunoreactivity was present in four cases.

Ocular vessels
Central retinal vessels in the papillary region
Distinct MT1-IR in the adventitia of central retinal arteries and veins was observed in all cases (++ to +++) in intensity). No difference in the intensity of staining between the arteries and veins was found (see Fig 2, Table 2).

Retinal vessels
The same staining pattern as described for the central retinal vessels in the papillary region was also found in the adventitia of the small retinal vessels located in the ganglion cell layer and in the inner plexiform layer (compare Fig 2, Table 2).

Choroidal and ciliary vessels
In two of six cases, low levels of MT1-IR were observed in the choroidal vessels, mainly in the peripapillary region. Ciliary vessels were not labelled (see Table 2).

<table>
<thead>
<tr>
<th>Case No</th>
<th>Age (years)</th>
<th>Time between death and necropsy (hours)</th>
<th>Ganglion cells</th>
<th>Amacrine cells</th>
<th>Photoreceptor cells (rods&gt;cones)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>59</td>
<td>12.40</td>
<td>+++ (&gt;90%)</td>
<td>−</td>
<td>+++</td>
</tr>
<tr>
<td>2</td>
<td>97</td>
<td>06.10</td>
<td>+++ (&gt;90%)</td>
<td>+ (3–4)</td>
<td>+++</td>
</tr>
<tr>
<td>3</td>
<td>88</td>
<td>31.45</td>
<td>++ (&gt;90%)</td>
<td>+ (8)</td>
<td>++</td>
</tr>
<tr>
<td>4</td>
<td>76</td>
<td>23.45</td>
<td>+++ (&gt;90%)</td>
<td>+ (6)</td>
<td>++</td>
</tr>
<tr>
<td>5</td>
<td>91</td>
<td>24.32</td>
<td>++</td>
<td>+ (4–2)</td>
<td>+++</td>
</tr>
<tr>
<td>6</td>
<td>85</td>
<td>18.10</td>
<td>+++</td>
<td>+ (21)</td>
<td>+++</td>
</tr>
<tr>
<td>7</td>
<td>35</td>
<td>14.45</td>
<td>++</td>
<td>+ (5)</td>
<td>+++++</td>
</tr>
</tbody>
</table>

Figure 1  Immunohistochemical staining of MT1 receptors in the retinal ganglion cell layer (arrowheads) and in cells of the inner nuclear layer (A) and in the photoreceptor layer (rods = stars, cones = arrows) (B) of the central part of the retina. (C) represents a negative control. RCL = rod and cone layer; ONL = outer nuclear layer; OPL = outer plexiform layer; INL = inner nuclear layer; IPL = inner plexiform layer; GCL = ganglion cell layer. Magnification: 40× (A); 20× (B, C).
Cornea
Some MT1-IR was found in the endothelial cell layer, in keratocytes, and in the epithelial cell layer (compare Fig 3, Table 3).

DISCUSSION
We detected MT1-IR primarily in the inner segments of rods and cones, retinal ganglion cells, and in a few cells of the inner nuclear layer. In addition, MT1-IR was present in the adventitia of retinal arteries and veins, predominantly in the papillary region, but was absent from ciliary and choroidal vessels. Mild staining of corneal endothelial cells and keratocytes was observed in all but two eyes.

In our study, it was most impressive that all photoreceptor cells revealed distinct MT1 immunoreactivity in their inner segments. Moreover, MT1-IR extended as an immunoreactive band throughout the whole photoreceptor cell layer. Recent studies in rodents failed to demonstrate MT1-IR in photoreceptor cells. Using in situ hybridisation, Wiechmann and coworkers, however, demonstrated melatonin mRNA in photoreceptor segments of the frog retina. Therefore, interspecies differences may exist. The role of melatonin in photoreceptor function is as yet only partially disclosed. Several lines of evidence suggest that retinal melatonin is mainly synthesised in the photoreceptor cells, where it has been proposed to have a role as a scavenger of free radicals. Furthermore, it has been shown that melatonin reduces nitric oxide induced lipid peroxidation in rat retinal homogenate.

On the other hand, melatonin was reported to mediate light damage to photoreceptor cells by an as yet unknown mechanism. It has been suggested that melatonin may mediate inhibition of dopamine release, thus resulting in the
loss of neuroprotective action of dopamine on the photoreceptor cells. Dopamine inhibits outer segment disc shedding of photoreceptors, and dopamine D2-like receptors have been identified on rodent photoreceptor cells. Melatonin and dopamine most probably act as opponents; both substances are synthesised within the retina in a circadian rhythm, but while melatonin is synthesised and released at night, dopamine synthesis and release is stimulated by light.

About 90% of the retinal ganglion cells revealed MT1-IR in their somata and dendritic processes. This is interesting in light of the recent discovery of phototransduction by retinal ganglion cells that set the circadian pacemaker, together with identification of melanopsin in ganglion cells, as a putative photoreceptor molecule.

In six of eight cases single amacrine cells presented MT1-IR. The slight MT1 labelling of the inner plexiform layer observed in this study might correspond to the binding sites on the dendritic processes of ganglion and amacrine cells. Our results are in agreement with previous findings in rodents. In the latter study, MT1 positive amacrine cells have been found to be dopaminergic and GABAergic. As a consequence, modulation of dopamine release by melatonin via enhancement of GABA activity was hypothesised.

We also found distinct MT1-IR in central retinal arteries and veins and also in small retinal vessels located in the ganglion cell layer and in the inner plexiform layer.

In two of six cases, we observed low levels of MT1-IR in choroidal vessels, mainly in the peripapillary region. Ciliary vessels, however, were not labelled. MT1-IR of the retinal vessels was localised to the adventitia of the vessel walls, corresponding to our previous findings in human cerebral vessels. MT1 receptors are supposed to mediate vasoconstriction. Our observation suggests that melatonin exerts its effect, if any, on retinal vascular smooth muscle in an indirect way.

### Table 2
Intensity of specific immunoreactivity on a semiquantitative scale of +/+++ for the central retinal artery and vein, retinal, and choroidal vessels

<table>
<thead>
<tr>
<th>Case No</th>
<th>Central retinal artery</th>
<th>Central retinal vein</th>
<th>Retinal vessels</th>
<th>Choroidal vessels</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>–</td>
</tr>
<tr>
<td>6</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>–</td>
</tr>
</tbody>
</table>

### Table 3
Intensity of specific immunoreactivity on a semiquantitative scale of +/+++ for corneal endothelial cells, keratocytes, and corneal epithelial cells

<table>
<thead>
<tr>
<th>Case No</th>
<th>Corneal endothelial cells</th>
<th>Keratocytes</th>
<th>Corneal epithelial cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>3</td>
<td>+</td>
<td>–</td>
<td>++</td>
</tr>
<tr>
<td>4</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>+</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td>6</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

![Figure 3](image1.png)

**Figure 3** Immunohistochemical staining of the MT1 receptor in the cornea. Endothelial cell layer (A, arrow), keratocytes (A, arrowheads) and epithelial cell layer (B, arrow). (C) and (D) represent the corresponding negative controls. Magnification: 40×: A–D.
In addition, we observed mild staining of corneal endothelial cells, keratocytes, and corneal epithelial cells. Previous animal studies led to the conclusion that retinal melatonin is not involved in the generation of the corneal mitotic rhythm.18-20 In these studies, however, retinal photoreceptors were supposed to be the only source of ocular melatonin. Japanese quail eyes were treated with formoguanamine hydrochloride (FG), which induces photoreceptor degeneration. The fact that the corneal mitotic rhythm was maintained despite FG treatment led the authors to the conclusion that melatonin was not involved in the corneal mitotic rhythm. More recently, it has become evident that melatonin is not only synthesised by the pineal gland and by the retina, but also in various other tissues, including leucocytes, platelets, endothelial cells,21,22 and skin cultures.23 This led us to speculate that melatonin of non-retinal origin might be involved in the circadian mitotic rhythm of the cornea, possibly via activation of the MT1 receptors identified in the cornea.

However, our study has some limitations that need to be discussed. Firstly, we examined only eyes of older individuals, and therefore cannot exclude changes with age such as, for example, a downregulation of melatonin receptors with increasing age as described in an animal model.24 Secondly, the majority of the examined eyes originated from postmenopausal females. It is known that female reproductive hormones modulate the expression of vascular melatonin receptors in the rat.25 Therefore, our results may be somewhat different in men and premenopausal women. Furthermore, even though we found positive MT1-IR in the adventitia of the retinal vessels, we cannot completely exclude some diffusion of the label from one layer to the next in our postmortem eyes. Therefore, also MT1-IR of the smooth muscle cell layer might be present in our cases. On the other hand, we performed α-smooth muscle actin staining in adjacent sections using specific monoclonal antibodies. α-Smooth muscle actin stained the tunica media in all sections, thereby indicating that MT1-IR is present in the adventitia and not in the muscular layer.

Future studies should address this critical issues. Preliminary data also indicate that the distribution of MT1 receptors is altered in patients with neurodegenerative diseases like Alzheimer’s disease (unpublished data).

The highly selective immunostaining of retinal arteries and veins implies a possible role for melatonin in retinal vessel function and also warrants further investigation.

ACKNOWLEDGEMENTS
The authors thank Miriam Vonlanthen for her technical assistance.

Lena Brydon and Ralf Jockers were supported by grants from the CNRS, the Université Paris VII, the Association pour la Recherche sur le Cancer (ACR No 513).

Authors’ affiliations
P Meyer, M Poché, J Flammer, University Eye Clinic, Basle, Switzerland.
A Wirz-Justice, E Savaskan, Department of Gerontopsychiatry, Center for Chronobiology, Basle, Switzerland.
L Brydon, R Jockers, Institut Cochin de Génétique Moléculaire, Paris, France.
K U Loeffler, University Eye Clinic, Bonn, Germany.

REFERENCES